Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TP 271 (Primary) ; TP 271
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions
  • Sponsors Tetraphase Pharmaceuticals

    • Most Recent Events

    • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 08 Nov 2018 According to a Tetraphase Pharmaceuticals media release, this study is expected to complete in 2Q 2019.
    • 18 Oct 2018 Planned End Date changed from 31 Oct 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top